📌 Is ABBV a Buy right now?
According to Ultra Stock Analysis Pro, AbbVie Inc. (ABBV) is currently rated WAIT (Signal Strength: 0/7). The long-term fundamentals are stable (P/E: 88.4, Revenue Growth: +10.0%), while short-term technicals show a bearish trend (RSI: 38). Consider waiting for support confirmation near $242.36 before adding exposure.
For the latest stock analysis and interactive charts:
📊 Open ABBV Analysis ↗
Why this rating?
The Ultra Stock Analysis algorithm has assigned a WAIT rating to ABBV based on a confluence of 3 distinct factors:
📊 Confidence Interval:
Based on 7+ years of historical data, signals with this specific technical fingerprint have resulted in a positive return 70% of the time over a medium-term (months) hold period, with an average return of +12.7% per trade.
To assist with risk management, here are the three most probable paths for ABBV over the next trading week:
🟢 The Bull Case (Probability: 20%)
If ABBV reclaims the $242.36 resistance level (Bollinger Upper), algorithmic targets shift to $249.14. This move would likely be driven by continued sector rotation into Healthcare.
🔴 The Bear Case (Probability: 50%)
Failure to hold the $196.90 support zone (Bollinger Lower) triggers a defensive stop-loss signal. In this scenario, the algorithm projects a slide toward the $191.20 liquidity zone (-8.7% from current price).
🟡 The Base Case (Sideways)
Given the current ADX of 25 (strong trend), momentum suggests a directional move is imminent between $196.90 and $242.36 until a volume catalyst occurs.
⚠️ These scenarios are algorithm-generated projections based on technical analysis, not financial advice. Past performance does not guarantee future results.
| TECHNICAL METRICS | VALUE | FUNDAMENTAL METRICS | VALUE |
|---|---|---|---|
| Current Price | $209.40 | Market Cap | $370.4B |
| Past Win Rate (Backtest) | 70.0% | Forward P/E | 13.0x |
| Past Total Return | +59.1% | Analyst Target | $249.14 |
| RSI / Trend Strength | 38 / 25 | Upside to Target | +19.0% |
| MACD Signal | Bearish | Revenue Growth | +10.0% |
| Profit Factor | 3.31 | Institutional Own. | 76.4% |
| Open Position | No open position | Analyst Ratings | 20 Buy / 8 Hold / 1 Sell |
WAIT FOR ENTRY - Monitor for confluence score >= 5 with proper risk management using stop loss set at 2-3x the 14-day ATR volatility.
Both strategies analyzed independently. Conservative uses fixed 2.0x ATR stops. Hybrid adapts stops based on position profit (tighter as profit grows).
Fixed 2.0x ATR Stop Loss
Waiting for entry signal...
Entry Stop: $198.01 ({atr_multiplier}x ATR)
Backtest Results (Since 2018):
Past Win Rate
70%
Past Total Return
+59.1%
Max Drawdown
-13.2%
Avg Trade
+12.7%
Trades
10
Adaptive ATR Stop Loss (1.0-2.75x)
Waiting for entry signal...
Entry Stop: $200.86 ({atr_multiplier}x ATR)
Backtest Results (Since 2018):
Past Win Rate
76%
Past Total Return
+77.6%
Max Drawdown
-11.1%
Avg Trade
+8.5%
Trades
17
Current Price
$209.40
Buy Stop Loss
$198.01
Distance: 5%
Conservative 2.0x
Position Stop Loss
$198.01
Distance: 5%
Hybrid 2.00x
ATR 14 Day
$5.70
Volatility
ADX Strength
25.2
Strong trend
New position - Standard stop loss levels
ADX: 20-25 = Emerging trend | 25-50 = Strong trend | 50+ = Very strong
| Indicator | Value | Signal |
|---|---|---|
| EMA 20 | $215.82 | Bearish |
| EMA 50 | $220.37 | Bearish |
| RSI (14) | 37.6 | Weak - potential support |
| Trend Strength (ADX) | 25.2 | Strong trend (25-50) |
Recent upgrades, downgrades, and price target changes (last 90 days)
| Firm | Action | From → To | Date |
|---|---|---|---|
| RBC Capital | INITIATED | Outperform | Feb 25, 2026 |
| Barclays | INITIATED | Overweight | Feb 20, 2026 |
| Wolfe Research | DOWNGRADE | Outperform → Peer Perform | Jan 08, 2026 |
| Average Target: | $249.14 | High Target: | $299.00 |
| Current Price: | $209.40 | Low Target: | $184.00 |
| Upside to Average: | +19.0% | Number of Analysts: | 29 |
Based on backtest performance (Win Rate: 70.0%, Avg Return: +12.7%) and analyst consensus (Target: $249.14, +19.0% upside), an OVERWEIGHT exposure may be considered. Risk/Reward ratio of 1.27:1 suggests moderate risk-adjusted returns. No current position - opportunity to establish entry at favorable technical levels.
AbbVie Inc. operates in the Healthcare sector (Drug Manufacturers - General). Current valuation of 13.0x forward P/E reflects discounted multiples relative to growth prospects. Operating margin of 34.1% shows strong profitability.
Fundamental Outlook: Moderate Growth - Monitoring profitability amid revenue expansion
Overall Score: 3.6/10 - Slightly Bullish
JNJ's Innovative Medicine unit eyes Q1 growth on key drug momentum, but biosimilar pressure and Stelara's decline may weigh on results....
Over the last 7 days, the United States market has experienced a 1.6% decline, yet it has shown resilience with a 15% rise over the past year and an a...
The stock has averaged annual gains of 16.2% over the past decade, and it sports a generous dividend yield, too....
It has been a tough market. The uncertainty surrounding the war with Iran is taking a toll. But one stock in particular should be worth enduring possi...
Healthcare spending doesn’t stop during recessions. That structural reality is the core argument for owning Vanguard Health Care ETF (NYSEARCA:VHT), a...
The news sentiment is moderately bullish, showing generally positive coverage with some caution. Market perception appears favorable but not overwhelmingly positive. This neutral-to-positive sentiment suggests steady conditions without extreme optimism.
| Metric | Value |
|---|---|
| Market Cap | $370.4B |
| P/E Ratio (Forward) | 13.0 |
| EPS (Forward) | $16.12 |
| Dividend Yield | 3.30% |
| 52-Week Range | $164.39 - $244.81 |
| Beta | 0.33 |
| Avg Volume | 7.2M |
Comprehensive Technical Data for Quantitative Analysis
| Indicator | Value | Indicator | Value |
|---|---|---|---|
| Close Price | $209.40 | Volume | 5.7M |
| EMA 20 | $215.82 | EMA 50 | $220.37 |
| EMA 200 | $213.54 | Current Price | $209.40 |
| RSI (14) | 37.61 | MACD | -5.175 |
| MACD Signal | -3.934 | MACD Histogram | -1.241 |
| Trend Strength (ADX) | 25.17 | Volatility (ATR 14) | $5.70 |
| Bollinger Upper | $242.36 | Bollinger Lower | $196.90 |
| Stochastic %K | 25.16 | Stochastic %D | 18.81 |
| VWAP | $210.67 | Bollinger Middle | $219.63 |
| Confluence Score | 0/7 | Trade Signal | NONE |
Comprehensive Fundamental Data for Financial Analysis
| Valuation Metrics | Performance | ||
|---|---|---|---|
| Market Cap | $370.4B | Revenue | $61.2B |
| Forward P/E | 13.0 | Revenue Growth | +10.0% |
| Trailing P/E | 88.4 | Gross Margin | 71.6% |
| Price/Sales | 6.06 | Operating Margin | 34.1% |
| Price/Book | -113.19 | Profit Margin | 6.9% |
| PEG Ratio | 0.50 | ROE | 6225.0% |
| Enterprise Value | $433.4B | Free Cash Flow | $18.3B |
Comprehensive Trading Performance and Position Details
| Entry Date | Exit Date | Entry Price | Exit Price | Return % | Result |
|---|---|---|---|---|---|
| 2019-08-07 | 2020-03-13 | $49.14 | $66.93 | +36.19% | Win |
| 2020-05-12 | 2021-09-08 | $71.97 | $93.28 | +29.60% | Win |
| 2021-11-02 | 2022-05-23 | $99.69 | $129.04 | +29.44% | Win |
| 2022-07-07 | 2022-08-04 | $132.50 | $122.23 | -7.75% | Loss |
| 2022-09-30 | 2023-01-24 | $118.08 | $132.51 | +12.22% | Win |
| 2023-03-03 | 2023-03-09 | $140.02 | $132.21 | -5.58% | Loss |
| 2023-06-01 | 2024-04-16 | $120.83 | $153.15 | +26.75% | Win |
| 2024-04-26 | 2024-11-13 | $150.40 | $163.28 | +8.56% | Win |
| 2025-01-22 | 2025-04-10 | $163.71 | $168.55 | +2.96% | Win |
| 2025-09-11 | 2026-03-23 | $216.90 | $204.93 | -5.52% | Loss |
Summary: 10 total trades | Strategy: No Active Position
Disclaimer: This report is for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results. Technical analysis based on historical data through 2026-03-27. Fundamental data auto-fetched from Yahoo Finance. Please conduct your own due diligence before making investment decisions.
Report Generated: March 29, 2026 at 12:21 PM
Ultra Stock Analysis Pro - Comprehensive Technical & Fundamental Analysis